Relay Therapeutics (RLAY) Stock Forecast & Price Target

$4.16 -0.10 (-2.35%)

(As of 12/20/2024 05:45 PM ET)

Relay Therapeutics - Analysts' Recommendations and Stock Price Forecast (2025)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Moderate Buy

Based on 11 Analyst Ratings

Sell
0

Hold
1

Buy
10

Based on 11 Wall Street analysts who have issued ratings for Relay Therapeutics in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 11 analysts, 1 has given a hold rating, and 10 have given a buy rating for RLAY.

Consensus Price Target

$20.50
392.79% Upside

According to the 11 analysts' twelve-month price targets for Relay Therapeutics, the average price target is $20.50. The highest price target for RLAY is $28.00, while the lowest price target for RLAY is $16.00. The average price target represents a forecasted upside of 392.79% from the current price of $4.16.

Get the Latest News and Ratings for RLAY and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Relay Therapeutics and its competitors.

RLAY Analyst Ratings Over Time

Type	Current Forecast 12/22/23 to 12/21/24	1 Month Ago 11/22/23 to 11/21/24	3 Months Ago 9/23/23 to 9/22/24	1 Year Ago 12/22/22 to 12/22/23
Strong Buy	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)	1 Strong Buy rating(s)
Buy	10 Buy rating(s)	9 Buy rating(s)	9 Buy rating(s)	7 Buy rating(s)
Hold	1 Hold rating(s)	1 Hold rating(s)	1 Hold rating(s)	2 Hold rating(s)
Sell	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)
Consensus Price Target	$20.50	$21.22	$21.11	$24.61
Forecasted Upside	392.79% Upside	357.38% Upside	181.48% Upside	118.96% Upside
Consensus Rating	Moderate Buy	Moderate Buy	Moderate Buy	Moderate Buy

Could This Tiny Device Help You Make an Extra $30k a Year? (Ad)

I believe it’s going to power Elon Musk’s next AI revolution… A revolution he believes will be worth more than $9 trillion. That’s nearly 10 times more money than the market caps of Tesla… SpaceX… PayPal… Neuralink… and X… COMBINED.

Click here to see the details because I believe a lot of people will get rich.

RLAY Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

RLAY Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Relay Therapeutics Stock vs. The Competition

Type	Relay Therapeutics	Medical Companies	S&P 500
Consensus Rating Score	2.91	2.81	2.51
Consensus Rating	Moderate Buy	Moderate Buy	Moderate Buy
Predicted Upside	392.79% Upside	25,828.60% Upside	14.54% Upside
News Sentiment Rating	Positive News See Recent RLAY News	Positive News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Analyst Name	Action	Rating	Price Target	Upside/Downside on Report Date
12/12/2024	JMP Securities 2 of 5 stars		Reiterated Rating	Market Outperform ➝ Market Outperform	$21.00 ➝ $21.00	+315.02%
12/4/2024	Leerink Partners 1 of 5 stars		Lower Target	Outperform ➝ Outperform	$19.00 ➝ $18.00	+310.02%
12/4/2024	HC Wainwright 2 of 5 stars		Lower Target	Buy ➝ Buy	$20.00 ➝ $16.00	+264.46%
9/16/2024	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Buy ➝ Buy	$28.00 ➝ $28.00	+250.00%
9/10/2024	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Buy ➝ Buy	$20.00 ➝ $24.00	+180.70%
9/10/2024	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Overweight ➝ Overweight	$14.00 ➝ $17.00	+97.90%
Get the Latest News and Ratings for RLAY and Related Stocks Enter your email address below to receive the latest news and analysts' ratings for Relay Therapeutics and its competitors with MarketBeat's FREE daily newsletter.
9/10/2024	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Overweight ➝ Overweight	$23.00 ➝ $21.00	+144.47%
9/10/2024	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	S. Richter Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$20.00	+110.30%
9/10/2024	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating		Downgrade	Outperform ➝ Market Perform
9/10/2024	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Upgrade	Hold ➝ Buy	$10.60 ➝ $16.00	+68.24%
2/22/2024	Leerink Partnrs Subscribe to MarketBeat All Access for the recommendation accuracy rating	A. Berens Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform
8/8/2023	SVB Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Outperform
4/19/2023	Raymond James Subscribe to MarketBeat All Access for the recommendation accuracy rating		Upgrade	Outperform ➝ Strong-Buy	$29.00	+149.57%
3/9/2023	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target		$45.00 ➝ $28.00	+65.58%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Saturday at 10:09 AM ET.

RLAY Forecast - Frequently Asked Questions

: According to the research reports of 11 Wall Street equities research analysts, the average twelve-month stock price forecast for Relay Therapeutics is $20.50, with a high forecast of $28.00 and a low forecast of $16.00.
: 11 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Relay Therapeutics in the last year. There is currently 1 hold rating and 10 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" RLAY shares.
: According to analysts, Relay Therapeutics's stock has a predicted upside of 392.79% based on their 12-month stock forecasts.
: Relay Therapeutics has been rated by research analysts at HC Wainwright, JMP Securities, and Leerink Partners in the past 90 days.
: Analysts like Relay Therapeutics more than other "medical" companies. The consensus rating score for Relay Therapeutics is 2.91 while the average consensus rating score for "medical" companies is 2.81. Learn more on how RLAY compares to other companies.

Stock Forecasts and Research Tools

Related Companies

Today's Ratings

Top Rated Stocks

More Ratings Tools

What most folks don’t know about oil (BIG missed opportunity) (Ad)

$1 Trillion… That’s how much Big Tech is set to spend on AI investment in the coming months—according to Goldman Sachs. This investment is driving an A.I. boom that’s being felt across many industries… Including a specific group of energy tickers since A.I. data centers use a massive amount of power. One of those tickers is CEG, up nearly 600% in the last 3 years… Combined with the upcoming presidential election, we have the recipe for a major shakeup in the market. You see, each time the U.S. elects a new president, one overlooked part of the energy sector tends to see a big move. Fact is… this energy niche is BOOMING.

And expects this underappreciated niche to continue rallying well into 2026.

This page (NASDAQ:RLAY) was last updated on 12/21/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Relay Therapeutics (RLAY) Stock Forecast & Price Target